GLENMARK PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLENMARK PHARMACEUTICALS have increased by 12.77% YoY .
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has increased by 30.05 % YoY. |
||
GLENMARK PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532296|NSE : GLENMARK]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹13,322 Cr | ₹11,813 Cr | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr |
| Expenses | ₹10,970 Cr | ₹10,618 Cr | ₹9,948 Cr | ₹9,985 Cr | ₹8,860 Cr |
| Operating Profit (Excl OI) | ₹2,351 Cr | ₹1,195 Cr | ₹1,635 Cr | ₹2,320 Cr | ₹2,084 Cr |
| Other Income | ₹114 Cr | ₹840 Cr | ₹289 Cr | ₹167 Cr | ₹50 Cr |
| Interest | ₹207 Cr | ₹516 Cr | ₹349 Cr | ₹298 Cr | ₹353 Cr |
| Depreciation | ₹486 Cr | ₹582 Cr | ₹569 Cr | ₹487 Cr | ₹444 Cr |
| Profit Before Tax | ₹1,399 Cr | ₹36 Cr | ₹240 Cr | ₹1,441 Cr | ₹1,382 Cr |
| Profit After Tax | ₹1,047 Cr | ₹-1,831 Cr | ₹-90 Cr | ₹994 Cr | ₹970 Cr |
| Consolidated Net Profit | ₹1,047 Cr | ₹-1,502 Cr | ₹297 Cr | ₹942 Cr | ₹970 Cr |
| Earnings Per Share (Rs) | ₹48.26 | ₹37.11 | ₹-53.21 | ₹10.53 | ₹33.37 |
| PAT Margin (%) | 3.93 | 3.65 | -6.61 | -0.32 | 3.57 |
| ROE(%) | 14.10 | 12.56 | -21.18 | -0.97 | 12.33 |
| ROCE(%) | 20.35 | 16.16 | 4.88 | 4.43 | 14.19 |
| Total Debt/Equity(x) | 0.00 | 0.25 | 0.13 | 0.46 | 0.40 |
Key Financials |
||
| Market Cap | : | ₹ 65,639.7 Cr |
| Revenue (TTM) | : | ₹ 17,736.6 Cr |
| Net Profit(TTM) | : | ₹ 1,797.8 Cr |
| EPS (TTM) | : | ₹ 63.7 |
| P/E (TTM) | : | 36.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 1.6% | 4% | 15.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -3% | -2.6% | 21.3% |
| DIVIS LABORATORIES | -0.5% | 17% | 43.8% |
| TORRENT PHARMACEUTICALS | 0.6% | 2.7% | 35.5% |
| CIPLA | -2.2% | 0.8% | -2.4% |
| DR REDDYS LABORATORIES | -1.1% | -1.6% | -0.8% |
| MANKIND PHARMA | -1% | -3.7% | -1.9% |
| LUPIN | -0.8% | -7.5% | 16.6% |
| ZYDUS LIFESCIENCES | -4.1% | -0.9% | 21.9% |
GLENMARK PHARMACEUTICALS Revenues
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 12.77 % |
| 5 Yr CAGR | 5.04 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹13,322 Cr | 12.77 | |
| Mar2025 | ₹11,813 Cr | 1.98 | |
| Mar2024 | ₹11,583 Cr | -5.86 | |
| Mar2023 | ₹12,305 Cr | 12.44 | |
| Mar2022 | ₹10,944 Cr | - | |
GLENMARK PHARMACEUTICALS Operating Profit
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 96.71 % |
| 5 Yr CAGR | 3.06 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,351 Cr | 96.71 | |
| Mar2025 | ₹1,195 Cr | -26.89 | |
| Mar2024 | ₹1,635 Cr | -29.53 | |
| Mar2023 | ₹2,320 Cr | 11.32 | |
| Mar2022 | ₹2,084 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 74.41 % |
| 5 Yr CAGR | -1.89 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 17.65% | 74.41 | |
| Mar2025 | 10.12% | -28.33 | |
| Mar2024 | 14.12% | -25.13 | |
| Mar2023 | 18.86% | -1.00 | |
| Mar2022 | 19.05% | - | |
GLENMARK PHARMACEUTICALS Profit After Tax
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | Positive |
| 5 Yr CAGR | 1.93 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,047 Cr | Positive | |
| Mar2025 | ₹-1,502 Cr | Negative | |
| Mar2024 | ₹297 Cr | -68.44 | |
| Mar2023 | ₹942 Cr | -2.92 | |
| Mar2022 | ₹970 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 7.67 % |
| 5 Yr CAGR | 2.43 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 3.93 % | 7.67 | |
| Mar2025 | 3.65 % | Positive | |
| Mar2024 | -6.61 % | Negative | |
| Mar2023 | -0.32 % | Negative | |
| Mar2022 | 3.57 % | - | |
GLENMARK PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 30.05 % |
| 5 Yr CAGR | 9.66 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹48 | 30.05 | |
| Mar2025 | ₹37 | Positive | |
| Mar2024 | ₹-53 | Negative | |
| Mar2023 | ₹11 | -68.44 | |
| Mar2022 | ₹33 | - | |
GLENMARK PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 25.93 % |
| 5 Yr CAGR | 9.43 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 20.35% | 25.93 | |
| Mar2025 | 16.16% | 231.15 | |
| Mar2024 | 4.88% | 10.16 | |
| Mar2023 | 4.43% | -68.78 | |
| Mar2022 | 14.19% | - | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,326.0 |
| Current MarketCap | : | ₹ 65,639.7 Cr |
| Updated EOD on | : | Aug 17,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.6% |
4% |
15.9% |
| SENSEX | -1% |
0.7% |
-3.6% |
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 150 MIDCAP INDEX | 0.2% | 2.1% | 10.2% |
| BSE 500 MOMENTUM 50 | 0.1% | 3.2% | NA |
| BSE 400 MIDSMALLCAP INDEX | 0% | 1.7% | 9.3% |
| BSE MOMENTUM INDEX | -0.4% | 5.4% | 3.3% |
| BSE 1000 | -0.5% | 1.7% | 4.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY ALPHA 50 | 0.3% | 4.4% | 10.2% |
| NIFTY500 MOMENTUM 50 | 0.1% | 2.4% | 7% |
| NIFTY MIDCAP150 MOMENTUM 50 | 0.1% | 2.4% | 5.9% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 0% | 3.1% | 8.3% |
| NIFTY MIDCAP 100 | -0.1% | 1.8% | 12.1% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS Financials
How the annual revenues of GLENMARK PHARMACEUTICALS have changed ?
The Revenues of GLENMARK PHARMACEUTICALS have increased by 12.77% YoY .
How the Earnings per Share (EPS) of GLENMARK PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has increased by 30.05 % YoY .
Check out Intrinsic Value of Peers of GLENMARK PHARMACEUTICALS
Compare Stock Analytics of Peers of GLENMARK PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
